ArticleThe World Allergy Organization journal2018
Improvement of patient-reported outcomes in severe allergic asthma by omalizumab treatment: the real life observational PROXIMA study.
Article in The World Allergy Organization journal, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 33 citations in OpenAlex.
- Relationship between knowledge, adherence-related behaviors and self-management with response to monoclonal antibody therapy in patients with severe asthma.Scientific reports · 2026Article
- Real-World Effectiveness of Omalizumab Treatment in Adult Asthma Patients.Yonsei medical journal · 2025Article
- Pre-asthma: a useful concept? A EUFOREA paper. Part 2-late onset eosinophilic asthma.Frontiers in allergy · 2024Review
- Patient and physician perspectives on biological treatment in severe asthma: a Severe Asthma Network Italy survey.ERJ open research · 2023Article
- Asthma Phenotypes in the Era of Personalized Medicine.Journal of clinical medicine · 2023Review
- Roles of real-world evidence in severe asthma treatment: challenges and opportunities.ERJ open research · 2023Article
- The "real-world" effectiveness and safety of omalizumab in patients with uncontrolled persistent allergic asthma in Slovakia: a subgroup analysis of the eXpeRience study.Postepy dermatologii i alergologii · 2023Article
- Oral Corticosteroid Reduction Between Biologics Initiated and Non-Initiated Patients with Severe Asthma.Journal of asthma and allergy · 2023Article
- Real-world effectiveness of omalizumab for severe allergic asthma treatment in Colombia.BMC pulmonary medicine · 2022Observational
- Effects of anti-IL5 biological treatments on blood IgE levels in severe asthmatic patients: A real-life multicentre study (BIONIGE).Clinical and translational allergy · 2022Article
- Sex, Allergic Diseases and Omalizumab.Biomedicines · 2022Review
- Omalizumab: An Optimal Choice for Patients with Severe Allergic Asthma.Journal of personalized medicine · 2022Review
- Real-life Effectiveness of Omalizumab in Patients with Severe Allergic Asthma: RELIEF Study.The open respiratory medicine journal · 2022Article
- Adherence to omalizumab: A multicenter "real-world" study.The World Allergy Organization journal · 2020Article
- Plasma Galectin-3 and urine proteomics predict FEVThe World Allergy Organization journal · 2020Article
- Effectiveness of omalizumab in patients with severe allergic asthma with and without chronic rhinosinusitis with nasal polyps: a PROXIMA study post hoc analysis.Clinical and translational allergy · 2020Article
- Article
- Physical Activity as a New Tool to Evaluate the Response to Omalizumab and Mepolizumab in Severe Asthmatic Patients: A Pilot Study.Frontiers in pharmacology · 2019Article
- Gender differences in asthma perception and its impact on quality of life: a post hoc analysis of the PROXIMA (Patient Reported Outcomes and XolairAllergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 8 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundData on the prevalence of perennial versus seasonal allergic asthma in Italy are lacking; moreover, there is limited evidence on the effect of omalizumab on patient-reported outcomes in Italian patients with severe allergic asthma. PROXIMA, an observational, multicenter study, was designed to assess the prevalence of perennial versus seasonal allergic asthma (cross-sectional phase) and the effect of omalizumab on improving illness perception, quality of life (QoL) and asthma control of Italian patients with severe allergic asthma (longitudinal phase).
methodsThe study included a cross-sectional phase (
resultsMost patients (95.8%) had perennial allergies; 81% had polysensitization. Of 99 patients in the per-protocol set, 95 (95.96% [95% CI: 89.98-98.89%]) achieved asthma control (ACQ < 4) at both 6 and 12 months of omalizumab treatment; ACQ score decreased after 6 and 12 months (
conclusionThis study demonstrated that in severe allergic asthma, omalizumab improves patient-reported outcomes such as patients' illness perception and QoL, while confirming improvement of asthma control and exacerbation rate reduction in Italian patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.